@article {LeeP5120, author = {Young Seok Lee and Ho Cheol Kim and Chang Keun Lee and Mi-Young Kim and Seungbong Han and Feghali-Bostwick Carol and Dong Soon Kim}, title = {The value of biomarkers in the rheumatoid arthritis related interstitial pneumonia}, volume = {42}, number = {Suppl 57}, elocation-id = {P5120}, year = {2013}, publisher = {European Respiratory Society}, abstract = {Background: Because of the highly variable clinical course, it is important to predict the prognosis of rheumatoid arthritis related interstitial pneumonia (RA-IP) at the time of diagnosis. The aim of the study was to find out the blood biomarker that can predict the disease progression and/or survival in the patients with RA-IP at the time of diagnosis.Method: The plasma levels of biomarkers (KL-6, MMP-7, IL-6, IL-22, and IL-32) were retrospectively compared with the clinical course of 79 patients with RA-IP (biopsy-proven: 33).Results: The mean age of the patients was 63 years and 45.6\% was male. The median follow-up period was 42 months. Among the 5 biomarkers, only KL-6 has clinical significance. KL-6 level was significantly higher in the patient with acute exacerbation (>=1447.80 ng/mL) compared to stable state (AUC, 0.938; P\<0.001). There was no correlation between the level of KL-6 and the treatment response. Among the patients followed-up without treatment (n=38), KL-6 level was higher in the patients whose disease was progressed compared to the patients remained in stable condition (AUC, 0.794; P=0.037) and higher frequency of reduction in lung function. Furthermore, univariate Cox hazard regression analysis showed KL-6 (HR, 1.003; P\<0.001) was a significant predictors of survival. The patients with high level of KL-6 (>=1005.40 ng/mL) had shorter survival compared to those with low levels of KL-6 (median survival: 46 vs. 77 months respectively) (AUC, 0.801).Conculusions: Our retrospective study suggested that blood level of KL-6 can be used as a marker of disease activity and prognostic predictor in the patients with RA-IP. More study in large number of the patients is warranted.}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/42/Suppl_57/P5120}, eprint = {https://erj.ersjournals.com/content/42/Suppl_57/P5120.full.pdf}, journal = {European Respiratory Journal} }